ImmunityBio (IBRX) Cash & Equivalents (2014 - 2026)

ImmunityBio (IBRX) has reported Cash & Equivalents for 13 consecutive years, with $205.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 238.27% year-over-year to $205.2 million; the TTM figure through Mar 2026 stood at $205.2 million (up 238.27% YoY), while the FY2025 annual figure was $88.3 million, down 38.41% from the prior year.
• Cash & Equivalents climbed to $205.2 million in Q1 2026 per IBRX's latest filing, from $88.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $265.5 million in Q4 2023 and bottomed at $36.4 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $114.9 million across 5 years, with a median of $104.6 million in 2022.
• Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 54.4% — and 2026, when it jumped 238.27%.
• ImmunityBio's Cash & Equivalents stood at $104.6 million in 2022, then jumped by 153.68% to $265.5 million in 2023, then slumped by 45.97% to $143.4 million in 2024, then plunged by 38.41% to $88.3 million in 2025, then soared by 132.29% to $205.2 million in 2026.
• Business Quant data shows IBRX's Cash & Equivalents at $205.2 million in Q1 2026, $88.3 million in Q4 2025, and $60.2 million in Q3 2025.